Switch From rhPTH1-84 to TransCon PTH With Individual Dose Adjustment in Adult Hypoparathyroidism—4-Week Results
We hereby report the first clinical data on switching treatment from rhPTH1-84 to 18 µg TransCon PTH independent of the prior rhPTH1-84 dose. Our data support discrete adaptation of the starting dose depending on the prior rhPTH1-84 dosage.
Authors
- Elena Tsourdi (ORCID: https://orcid.org/0000-0002-9582-1906)
- Ralf Schmidmaier (ORCID: https://orcid.org/0000-0003-3541-3588)
- Lorenz Christian Hofbauer (ORCID: https://orcid.org/0000-0002-8691-8423)
- Martina Blaschke (ORCID: https://orcid.org/0000-0001-5016-2591)
- Heide Siggelkow (ORCID: https://orcid.org/0000-0002-8366-8625)
- Christian Lottspeich (ORCID: https://orcid.org/0000-0002-1770-4392)
- Stefanie Hahner (ORCID: https://orcid.org/0000-0003-1616-8986)
- Christina Berr (ORCID: https://orcid.org/0000-0003-2307-1728)
- Klaus Peschke
Institutions
- University of Würzburg (DE)
- University Hospital Augsburg (DE)
- LMU Klinikum (DE)
- Universitätsmedizin Göttingen (DE)
- Endokrinologikum (DE)
- University of Göttingen (DE)
- Technische Universität Dresden (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1210/jendso/bvaf113
- Citations
- 3
- Primary Topic
- Thyroid and Parathyroid Surgery
- Type
- article
- Field-Weighted Citation Impact
- 6.02